Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026

Key Takeaway: SI-BONE, Inc. will report its financial results for Q3 2026 on November 2, 2026. The company will host a conference call at 1:30 p.m. PT to discuss these results. Investors can register for the call and access a live audio webcast on the company's website. SI-BONE is recognized for its advancements in procedural solutions for compromised bone health.

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is a leader in developing innovative solutions for compromised bone.
  • The company has a strong track record with over 150,000 procedures supported.
  • There is a wealth of clinical evidence backing SI-BONE's technologies.

Full Press Release Details

SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the third quarter of 2026 after market close on Monday, November 2, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/qa2u8o97/. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (Nasdaq: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 190 peer reviewed publications.
For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.
SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved

Investor Contact: Saqib Iqbal, investors@si-bone.com

Frequently Asked Questions

When will SI-BONE report its Q3 2026 financial results?

SI-BONE will report its Q3 2026 financial results on November 2, 2026.

What time is the SI-BONE conference call?

The conference call will begin at 1:30 p.m. Pacific Time.

How can investors listen to the conference call?

Investors can register for the call via a link provided in the announcement.

Where can I find the webcast of the conference call?

The live audio of the webcast will be available on SI-BONE's website.

Last updated: Oct 19, 2026